AstraZeneca's EGFR inhibitor Tagrisso has become the go-to therapy for EGFR-mutated non-small cell lung cancer (NSCLC), but now has competition from Johnson & Johnson's Rybrevant and Lazcluze ...

Tagrisso made sales of $5.8 billion last year and was bested by Rybrevant/Lazcluze in the MARIPOSA trial, although, so far J&J hasn't revealed sales figures for its product. The IV version has ...

Johnson & Johnson JNJ announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) rendered a positive opinion for the expanded use of the ...

The CHMP recommendation is for SC Rybrevant in combination with Lazcluze (lazertinib) for the first-line treatment of patients with advanced NSCLC with EGFR exon 19 deletion (ex19del) or L858R ...

Rybrevant showed durable responses in mCRC, with a median duration of response of 7.4 months for monotherapy and 5.8 months for combination therapy. The safety profile of Rybrevant was consistent with ...

The Committee for Medicinal Products for Human Use (CHMP) has recommended extending marketing authorisation for a subcutaneous (SC) formulation of Rybrevant for treating non-small cell lung cancer ...

Patients with non-small cell lung cancer saw a reduction in their risk of recurrence or death after surgery when treated with pre- and postsurgical Opdivo. Rybrevant plus Lazcluze, compared with ...

EU regulators have issued a positive opinion for the extension of the market authorization for a subcutaneous formulation of Johnson & Johnson's (NYSE:JNJ) Rybrevant ... JNJ) Lazcluze as a first ...